Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Surprise German Decision Boosts Jardiance Pricing Potential

Executive Summary

Boehringer Ingelheim/Lilly’s Jardiance has become one of the first of the newer antidiabetic agents to be viewed favorably by Germany's health technology assessment body, the G-BA. The surprise ruling paves the way for favorable pricing discussions.

Advertisement

Related Content

Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto
Cardiovascular Data To Propel Jardiance Ahead Of Rivals
Sensing No Room For Price Compromise, Janssen Pulls Invokana From Germany

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register